Free Trial
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel Free COIL Stock Alerts

Roquefort Therapeutics (COIL) Competitors

Roquefort Therapeutics logo
GBX 10.50 -0.50 (-4.55%)
As of 10:32 AM Eastern
Compare

COIL vs. CIR, TILS, VSN, FARN, and MPH

Should you buy Roquefort Therapeutics stock or one of its competitors? MarketBeat compares Roquefort Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Roquefort Therapeutics include Circassia Group (CIR), Tiziana Life Sciences (TILS), Verseon (VSN), Faron Pharmaceuticals Oy (FARN), and Mereo BioPharma Group plc (MPH.L) (MPH). These companies are all part of the "biotechnology" industry.

How does Roquefort Therapeutics compare to Circassia Group?

Circassia Group (LON:CIR) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Circassia Group has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Circassia Group's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Circassia GroupN/A N/A N/A
Roquefort Therapeutics -57,057.07%-18.30%-15.86%

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Circassia Group. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Circassia Group. Circassia Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Circassia Group Neutral
Roquefort Therapeutics Neutral

Circassia Group has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Circassia Group£27.90M0.00N/A£0.01N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

1.2% of Roquefort Therapeutics shares are owned by institutional investors. 36.2% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Circassia Group beats Roquefort Therapeutics on 6 of the 9 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Tiziana Life Sciences?

Roquefort Therapeutics (LON:COIL) and Tiziana Life Sciences (LON:TILS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Tiziana Life Sciences has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Tiziana Life Sciences' return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.30% -15.86%
Tiziana Life Sciences N/A N/A N/A

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Tiziana Life Sciences. Roquefort Therapeutics' average media sentiment score of 0.00 equaled Tiziana Life Sciences'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Tiziana Life Sciences Neutral

1.2% of Roquefort Therapeutics shares are held by institutional investors. 36.2% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tiziana Life Sciences has lower revenue, but higher earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A

Summary

Roquefort Therapeutics beats Tiziana Life Sciences on 5 of the 9 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Verseon?

Roquefort Therapeutics (LON:COIL) and Verseon (LON:VSN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Verseon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
VerseonN/AN/AN/A-£14.30N/A

Verseon has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Verseon's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.30% -15.86%
Verseon N/A N/A N/A

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Verseon. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Verseon. Roquefort Therapeutics' average media sentiment score of 0.00 equaled Verseon'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Verseon Neutral

1.2% of Roquefort Therapeutics shares are owned by institutional investors. 36.2% of Roquefort Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Roquefort Therapeutics and Verseon tied by winning 4 of the 8 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Faron Pharmaceuticals Oy?

Roquefort Therapeutics (LON:COIL) and Faron Pharmaceuticals Oy (LON:FARN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

1.2% of Roquefort Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of Faron Pharmaceuticals Oy shares are owned by institutional investors. 36.2% of Roquefort Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Faron Pharmaceuticals Oy shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Faron Pharmaceuticals Oy is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Faron Pharmaceuticals OyN/AN/A-£60.23M-£22.07N/A

Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market. Comparatively, Faron Pharmaceuticals Oy has a beta of 1.109, indicating that its stock price is 11% more volatile than the broader market.

Faron Pharmaceuticals Oy has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Faron Pharmaceuticals Oy's return on equity of 45.13% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.30% -15.86%
Faron Pharmaceuticals Oy N/A 45.13%-70.00%

In the previous week, Faron Pharmaceuticals Oy had 2 more articles in the media than Roquefort Therapeutics. MarketBeat recorded 3 mentions for Faron Pharmaceuticals Oy and 1 mentions for Roquefort Therapeutics. Faron Pharmaceuticals Oy's average media sentiment score of 0.85 beat Roquefort Therapeutics' score of 0.00 indicating that Faron Pharmaceuticals Oy is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roquefort Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Faron Pharmaceuticals Oy
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Faron Pharmaceuticals Oy beats Roquefort Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Roquefort Therapeutics compare to Mereo BioPharma Group plc (MPH.L)?

Roquefort Therapeutics (LON:COIL) and Mereo BioPharma Group plc (MPH.L) (LON:MPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

1.2% of Roquefort Therapeutics shares are held by institutional investors. 36.2% of Roquefort Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Mereo BioPharma Group plc (MPH.L) has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Mereo BioPharma Group plc (MPH.L)'s return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.30% -15.86%
Mereo BioPharma Group plc (MPH.L) N/A N/A N/A

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Mereo BioPharma Group plc (MPH.L). MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Mereo BioPharma Group plc (MPH.L). Roquefort Therapeutics' average media sentiment score of 0.00 equaled Mereo BioPharma Group plc (MPH.L)'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Mereo BioPharma Group plc (MPH.L) Neutral

Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Mereo BioPharma Group plc (MPH.L), indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Mereo BioPharma Group plc (MPH.L)N/AN/AN/A-£128.00N/A

Summary

Roquefort Therapeutics and Mereo BioPharma Group plc (MPH.L) tied by winning 4 of the 8 factors compared between the two stocks.

Get Roquefort Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for COIL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

COIL vs. The Competition

Export
MetricRoquefort TherapeuticsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£44.81M£441.31M£6.50B£2.72B
Dividend YieldN/A3.86%2.67%6.13%
P/E Ratio-0.483.1324.65366.57
Price / SalesN/A6,387.48500.8786,640.48
Price / Cash1.4913.1343.0527.87
Price / Book2.7587.1710.437.62
Net Income-£1.52M-£96.07M£3.56B£5.89B
7 Day Performance-0.53%0.96%-1.39%-1.31%
1 Month Performance47.87%2.52%0.86%0.85%
1 Year Performance-37.65%53.06%19.42%70.33%

Roquefort Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
COIL
Roquefort Therapeutics
N/AGBX 10.50
-4.6%		N/A-36.9%£44.81MN/AN/A9
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60MN/A11
VSN
Verseon
N/AN/AN/AN/A£112.24MN/AN/AN/A
FARN
Faron Pharmaceuticals Oy
N/AGBX 45
-2.2%		N/A-81.1%£89.78MN/AN/A34

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:COIL) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Forbes calls this a "golden era" for retirement income
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel